Supernus Pharma (SUPN) Reports Q4 EPS of $0.04

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.04, versus $0.57 reported last year. Revenue for the quarter came in at $159.1 million, versus $143.6 million reported last year.

GUIDANCE:

Supernus Pharma sees FY2022 revenue of $640-680 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Casey's General Stores (CASY) Tops Q1 EPS by 69c
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance